Findings

What do systematic reviews say?

13 questions · 13 findings · 2 reviews · Developmental, Psychosocial and Learning Problems

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 23.1%GRADE not reported 0 · 0%Very low 1 · 7.7%Low 9 · 69.2%Moderate 0 · 0%High 0 · 0%

Memantine vs placebo

Core symptoms of autism · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 181 participants
Very low

Memantine vs placebo

Adverse effects sufficient to stop treatment · Children aged 6 to 18 years with ASD

Memantine showed no clear difference in adverse effects Assessed by the study authors as those that were… compared with placebo (low certainty).

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
OR 0.64 [0.17, 2.39]
2 studies · 144 participants
Low

Memantine vs placebo

Language · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 144 participants
Low

Memantine vs placebo

Memory (specific cognitive function) · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Memantine vs placebo

Adaptive behaviour · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Memantine vs placebo

Hyperactivity · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Low

Memantine vs placebo

Irritability · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Low

Memantine vs placebo

Carer stress · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Institutional/home care · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Death · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Secondary outcome measure: cognitive abilities at the end of · people with Down syndrome

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 184 participants
Low

Memantine vs placebo

Behavioural problems: overall · people with Down syndrome

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 186 participants
Low

Memantine vs placebo

Adverse events · people with Down syndrome

Comparison 2: memantine showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
OR 0.45 [0.18, 1.17]
2 studies · 211 participants
Low